DOCSLIB.ORG

Paracetamol-Dextromethorphan-Hydrobromide-Phenylephrine-Hcl-Chlorpheniramine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Paracetamol-Dextromethorphan-Hydrobromide-Phenylephrine-Hcl-Chlorpheniramine Sr. Generic Name/Brand Name COMPOSITON Strength No. Each 5 ml. Contains:- Ofloxacin 50 mg Metronidazole Benzoate Ofloxacin, Metronidazole & 1 eq. to Metronidazole 120 mg Simethicone Suspension Simethicone 10 mg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. contains:- Liquid Paraffin 1.25 ml Milk of Magnesia & Liquid Milk of Magnesia 3.75 ml 2 Paraffin and Sodium Picosulfate Sodium Picosulfate 3.33 mg Oral Emulsion In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Ofloxacin 50 mg Ofloxacin & Metronidazole Metronidazole Benzoate 3 Suspension eq. to Metronidazole 100 mg In a flavoured syrupy base Colour : Approved colour used Each ml Contains Cyrproheptadine Hydrochloride 1.5 mg Cyproheptadine Hydrochloride 4 (Anhydrous) & Trcholine Citrate Drops Tricholine Citrate 55 mg In a flavoured syrupy base Each 5 ml. Contains:- Dextromethorphan Dextromethorphan Hydrobromide 15 mg Hydrobromide, Phenylephrine Phenylephrine Hydrochloride 5 mg 5 Hydrochloride & Chlorpheniramine Maleate 2 mg Chlorpheniramine Maleate In a flavoured syrupy base Syrup Colour : Approved colour used Each 5 ml. Contains:- Ambroxol Hydrochloride, Ambroxol Hydrochloride 15 mg Dextromethorphan Dextromethorphan Hydrobromide 10 mg 6 Hydrobromide & Cetirizine Cetirizine Hydrochloride 5 mg Hydrochloride Syrup In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Promethazine Hydrochloride 5 mg Promethazine Hydrochloride & 7 Paracetamol 125 mg Paracetamol Suspension In a flavoured syrupy base Colour : Approved colour used Sr. Generic Name/Brand Name COMPOSITON Strength No. Each 5 ml. Contains:- Sodium Feredetate Sodium Feredetate, Eq. to Elemental Iron 33 mg 8 Cyanocobalamin & Folic Acid Cyanocobalamin 15 mcg Syrup Folic Acid 1.5 mg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Fexofenadine Hydrochloride Fexofenadine Hydrochloride 30 mg 9 Suspension In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Levosalbutamol Sulphate Levosalbutamol, Ambroxol Eq to Levosalbutamol. 0.50 mg 10 Hydrochloride & Guaiphenesin Ambroxol Hydrochloride 15 mg Syrup Guaiphenesin 50 mg In a flavoured syrupy base Colour : Approved colour used Each ml Contains Domperidone 1 mg 11 Domperidone Suspension I.P. In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Ambroxol Hydrochloride 15 mg Ambroxol Hydrochloride, Chlorpheniramine Maleate 2 mg Chlorpheniramine Maleate, Dextromethorphan Hydrobromide 10 mg 12 Dextromethorphan Guaiphenesin 50 mg Hydrobromide, Guaiphenesin & Menthol 2.5 mg Menthol Syrup In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Azithromycin Dihydrate Azithromycin Oral Suspension 13 Eq. to Azithromycin 100 mg I.P. In a flavoured syrupy base Colour : Approved colour used Sr. Generic Name/Brand Name COMPOSITON Strength No. Each 5 ml. contains:- Vitamin A (as palmitate) 1500 IU Vitamin D3 100 IU Vitamin E (acetate) 3 mg Thiamine Hydrochloride 1.5 mg Riboflavin Sodium Phosphate 1.5 mg Pyridoxine Hydrochloride 1 mg Cyanocobalamin 1.5 mcg Niacinamide 5 mg Antioxidants, Vitamins, Ascorbic Acid 30 mg 14 Minerals & Iron Syrup D-Panthenol 2.5 mg L-Lysine Hydrochloride 40 mg Ferrous Gluconate 85.70 mg Eq. to Elemental Iron 10 mg Zinc Gluconate 34.85 mg Eq. to Elemental Zinc 5 mg Magnesium Gluconate 185.41 mg Eq. to Elemental Magnesium 10 mg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Potassium Citrate Monohydrate 1100 mg Potassium Citrate, Magnesium Magnesium Citrate 375 mg 15 Citrate & Vitamin B6 Syrup Vitamin B6 20 mg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Paracetamol, Paracetamol 170 mg Dextromethorphan Dextromethorphan Hydrobromide 5 mg 16 Hydrobromide, Phenylephrine Phenylephrine Hydrochloride 2.5 mg Hcl. & Chlorpheniramine Chlorpheniramine Maleate 1.5 mg Maleate Syrup In a flavoured syrupy base Colour : Approved colour used Each ml Contains Dicyclomine Hydrochloride 10 mg Dicyclomine Hydrochloride & 17 Activated Dimethicone 40 mg Activated Dimethicone Drops In a flavoured syrupy base Colour : Approved colour used Sr. Generic Name/Brand Name COMPOSITON Strength No. Each 15 ml. Contains :- Ferrous Glycine Sulphate Eq. to Elemental Iron 50 mg Folic Acid 0.5 mg Ferrous Glycine Sulphate, Folic Cyanocobalamin 7.5 mcg 18 Acid, Cyanocobalamin, Zinc & D- Zinc Sulphate Monohydrate Biotin Suspension Eq. to Elemental Zinc 2.5 mg D-Biotin 100 mcg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Levofloxacin Hemihydrate Levofloxacin & Ornidazole Eq. to Levofloxacin 125 mg 19 Suspension Ornidazole 125 mg In a flavoured syrupy base Colour : Approved colour used Each ml Contains Simethicone Emulsion Eq. to Simethicone(30%) 40 mg Simethicone, Dill Oil & Fennel 20 Dill Oil 0.005 ml Oil Oral Drops Fennel Oil 0.0007 ml In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Zinc Acetate Dihydrate 21 Zinc Acetate Syrup Eq. to Elemental Zinc 20 mg Mentholated Syrup Base Colour : Approved colour used Each 5 ml. Contains:- Ofloxacin 100 mg Ofloxacin & Metronidazole Metronidazole Benzoate 22 Suspension eq. to Metronidazole 200 mg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Paracetamol 125 mg Paracetamol, Phenylephrine Phenylephrine Hydrochloride 5 mg 23 Hcl. & Cetirizine Hcl. Suspension Cetirizine Hydrochloride 2 mg In a flavoured syrupy base Colour : Approved colour used Each ml Contains Betamethasone Sodium Phosphate Betamethasone Sodium 24 Eq. to Betamethasone 0.50 mg Phosphate Oral Drops In a flavoured syrupy base Colour : Approved colour used Sr. Generic Name/Brand Name COMPOSITON Strength No. Each 5 ml. Contains:- Carbonyl Iron Eq. to Elemental Iron 50 mg Iron, Zinc & Folic Acid 25 Zinc Sulphate 22 mg Suspension Folic Acid 1.5 mg In a flavoured syrupy base Colour : Approved colour used Each 15 ml. Contains :- Ferric Ammonium Citrate 165 mg Vitamin B1 2.0 mg Vitamin B2 2.0 mg Vitamin B6 1.0 mg Vitamin B12 7.5 mcg Protein Hydrolysate 20% 1000 mg Multivitamins With Protein 26 Niacinamide 15 mg Syrup D-Panthenol 1.5 mg L-Lysine Hydrochloride 30 mg Manganese Sulphate 1.0 mg Zinc Sulphate 2.0 mg Copper Sulphate 2.0 mg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Calcium Carbonate 625 mg Calcium Carbonate & Vitmain (Eq. to Elemental Calcium 250mg) 27 D3 Suspension Vitamin D3 125 I.U. In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Potassium Citrate 1100 mg Potassium Citrate & 28 Magnesium Citrate 375 mg Magnesium Citrate Oral Syrup In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Calcium Carbonate 625 mg Eq. to Elemental Calcium 250 mg Magnesium Hydroxide 180 mg Calcium, Magnesium, Zinc & Eq. to Elemental Magnesium 75 mg 29 Vitamin D3 Suspension Zinc Gluconate 14 mg Eq. to Elemental Zinc 2 mg Vitamin D3 200 I.U. In a flavoured syrupy base Colour : Approved colour used Sr. Generic Name/Brand Name COMPOSITON Strength No. Each 5 ml. Contains:- Dicyclomine Hydrochloride 2.5 mg Dicyclomine, Aluminium Dried Aluminium Hydroxide 200 mg 30 Hydroxide, Magnesium Oxide & Light Magnesium Oxide 100 mg Simethicone Suspension Simethicone 20 mg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Bromhexine Hydrochloride Bromhexine Hydrochloride 4 mg 31 Syrup In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Sodium Picosulfate Oral Sodium Picosulfate 5 mg 32 Solution BP In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Paracetamol 125 mg Paracetamol, Phenylephrine Phenylephrine Hydrochloride 2.5 mg 33 Hcl. & Chlorpheniramine Chlorpheniramine Maleate 1 mg Maleate Suspension In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Paracetamol 125 mg Paracetamol, Phenylephrine Phenylephrine Hydrochloride 5 mg Hydrochloride, Chlorpheniramine Maleate 0.5 mg 34 Chlorpheniramine Maleate, Sodium Citrate 60 mg Sodium Citrate and Menthol Menthol 1 mg Suspension In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Ferrous Ascorbate Ferrous Ascorbate and Folic eq. to Elemental Iron 30 mg 35 Acid Suspension Folic Acid 550 mcg Flavoured Syrupy Base Colour : Approved Colour used Each 5 ml. contains:- Paracetamol Paediatric Oral Paracetamol 250 mg 36 Suspension I.P. In a flavoured syrupy base Colour : Approved colour used Each 5 ml. contains:- Levocetirizine Hydrochloride Levocetirizine Hydrochloride 2.5 mg 37 Syrup In a flavoured syrupy base Colour : Approved colour used Sr. Generic Name/Brand Name COMPOSITON Strength No. Each 5 ml. contains:- Levocetirizine Dihydrochloride 2.5 mg Levocetirizine Dihydrochloride Montelukast Sodium 38 and Montelukast Syrup eq. to Montelukast 4 mg In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Ambroxol Hydrochloride 15 mg Ambroxol Hydrochloride, Guaiphenesin 50 mg 39 Guaiphenesin, Terbutaline Terbutaline Sulphate 1.25 mg Sulphate and Menthol Syrup Menthol 2.5 mg Flavoured Syrupy Base Colour : Approved Colour used Each 5 ml. Contains:- Magaldrate 400 mg Magaldrate and Simethicone 40 Simethicone 60 mg Suspension In a flavoured syrupy base Colour : Approved colour used Each 5 ml. Contains:- Cyproheptadine Hydrochloride Cyproheptadine Hydrochloride eq. to Anhydrous Cyproheptadine Hydrochloride2 mg 41 and Tricholine Citrate Syrup Tricholine Citrate (65%) 275 mg In a flavoured syrupy base Colour : Approved colour
Load more

Recommended publications
  • TR-348: Alpha-Methyldopa Sesquihydrate (CASRN 41372-08-1)
    NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 348 TOXICOLOGY AND CARCINOGENESIS STUDIES OF a/pha-METHYLDOPA SESQUIHYDRATE (CAS NO. 41372-08-1) IN F344/N RATS AND B6C3Fi MICE (FEED STUDIES) U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF a/p/)a-METHYLDOPA SESQUIHYDRATE (CAS NO. 41372-08-1) IN F344/N RATS AND B6C3Fi MICE (FEED STUDIES) June K. Dunnick, Ph.D., Chemical Manager NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 March 1989 NTP TR 348 NIH Publication No. 89-2803 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NOTE TO THE READER This study was performed under the direction of the K’ational Institute of Environmental Health Sci- ences as a function of the National Toxicology Program. The studies described in this Technical Re- port have been conducted in compliance with NTP chemical health and safety requirements and must meet or exceed all applicable Federal, state, and local health and safety regulations. Animal care and use were in accordance with the U.S. Public Health Service Policy on Humane Care and Use of Ani- mals. All NTP toxicology and carcinogenesis studies are subjected to a data audit before being pre- sented for public peer review. Although every effort is made to prepare the Technical Reports as accurately as possible, mistakes may occur. Readers are requested to identify any mistakes so that corrective action may be taken. Further, anyone who is aware of related ongoing or published studies not mentioned in this report is encouraged to make this information known to the NTP.
    [Show full text]
  • Adrenergic Agonist, Methoxamine, Reduces Exercise-Induced Asthma
    Eur Respir J 1989, 2, 409-414 Pretreatment with an inhaled a 1-adrenergic agonist, methoxamine, reduces exercise-induced asthma A.T. Dinh Xuan, M. Chaussain, J. Regnard, A. Lockhart PretreatmenJ with an inhaled a,-adrenergic agonist. methoxamine, reduces Laboratoire de Physiologie, Faculte de Medecine eurcise-induced asthma. A.T. Dinh Xuan, M. Chaussain, J. Regnard, A. Cochin Port-Royal et Laboratoires d'Exploration Lockhart. Fonctionnelle Respiratoire, Hopitaux Cochin et ABSTRACT: In order to assess the role of the bronchial circulation in the Saint Vincent de Paul, 75014 Paris, France. pathogenes.ls of exercise-.induced asthma (EIA), we conducted a double­ Correspondence: Dr A.T. Dinh Xuan, Laboratoire blind, randomlzed study of the effects of pretreatment with an inhaled a - 1 d 'Explorations Fonctionnelles, Pavilion Potain, adrenergic agonist, methoxamine (Mx), l.n nine asthmatic teenagers with Hopital Cochin, 27 Rue du Faubourg Saint known r..:rA. Exercise consisted of S min cycle ergometry at a submaximal, Jacques, 75014 Paris, France. constant work-load, while the subjecfs breathed dry air at ambient tem­ ) Keywords: Airway oedema; a.,-adrenoceptors; perature. Forced expiratory volume in one second (FEV1 was measured at ba...eJine, JS min after pretreatment of either Mx or saline, and ser ially bronchial circulation; exercise-induced asthma; methoxamine. after exercise. Mx significantly reduced the exercise-induced fa ll of FEV 1 without modifying baseline FEV1 In five of the eight subJec t~ , had li ttle or no effect In three and caused an acute asthmatic attack in the remaining Received: June, 1988; accepted after revision December 29, 1988. subject. Mx has p<>tent constrictor effects on both bronchial and vascular smooth muscles through stimulation of postjunctlonal a 1-nd renoceptors.
    [Show full text]
  • PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 Mg/Ml Β2-Adrenergic Stimulant Bronchodilator AA P
    PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 mg/mL 2-Adrenergic Stimulant Bronchodilator AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 10, 2014 Vaughan, Ontario L4K 4N7 Control Number: 172362 1 PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulfate Syrup House Standard 2 mg/mL THERAPEUTIC CLASSIFICATION 2–Adrenergic Stimulant Bronchodilator ACTIONS AND CLINICAL PHARMACOLOGY Orciprenaline sulphate is a bronchodilating agent. The bronchospasm associated with various pulmonary diseases - chronic bronchitis, pulmonary emphysema, bronchial asthma, silicosis, tuberculosis, sarcoidosis and carcinoma of the lung, has been successfully reversed by therapy with orciprenaline sulphate. Orciprenaline sulphate has the following major characteristics: 1) Pharmacologically, the action of orciprenaline sulphate is one of beta stimulation. Receptor sites in the bronchi and bronchioles are more sensitive to the drug than those in the heart and blood vessels, so that the ratio of bronchodilating to cardiovascular effects is favourable. Consequently, it is usually possible clinically to produce good bronchodilation at dosage levels which are unlikely to cause cardiovascular side effects. 2 2) The efficacy of the bronchodilator after both oral and inhalation administration has been demonstrated by pulmonary function studies (spirometry, and by measurement of airways resistance by body plethysmography). 3) Rapid onset of action follows administration of orciprenaline sulphate inhalants, and the effect is usually noted immediately. Following oral administration, the effect is usually noted within 30 minutes. 4) The peak effect of bronchodilator activity following orciprenaline sulphate generally occurs within 60 to 90 minutes, and this activity lasts for 3 to 6 hours. 5) Orciprenaline sulphate taken orally potentiates the action of a bronchodilator inhalant administered 90 minutes later, whereas no additive effect occurs when the drugs are given in reverse order.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Adrenoceptor Subtype 1Ian Marshall, Richard P
    Brifish Journal of Pharmacology (I995) 115, 781 - 786 1995 Stockton Press All rights reserved 0007-1188/95 $12.00 X Noradrenaline contractions of human prostate mediated by aClA- (cxlc) adrenoceptor subtype 1Ian Marshall, Richard P. Burt & *Christopher R. Chapple Department of Pharmacology, University College London, Gower Street, London WC1E 6BT and *Department of Urology, The Royal Hallamshire Hospital, Glossop Road, Sheffield SlO 2JF 1 The subtype of a1-adrenoceptor mediating contractions of human prostate to noradrenaline was characterized by use of a range of competitive and non-competitive antagonists. 2 Contractions of the prostate to either noradrenaline (pD2 5.5), phenylephrine (pD2 5.1) or methoxamine (pD2 4.4) were unaltered by the presence of neuronal and extraneuronal uptake blockers. Noradrenaline was about 3 and 10 times more potent than phenylephrine and methoxamine respectively. Phenylephrine and methoxamine were partial agonists. 3 Pretreatment with the alkylating agent, chlorethylclonidine (10-4 M) shifted the noradrenaline concentration-contraction curve about 3 fold to the right and depressed the maximum response by 31%. This shift is 100 fold less than that previously shown to be produced by chlorethylclonidine under the same conditions on OlB-adrenoceptor-mediated contractions. 4 Cumulative concentration-contraction curves for noradrenaline were competitively antagonized by WB 4101 (pA2 9.0), 5-methyl-urapidil (pA2 8.6), phentolamine (pA2 7.6), benoxathian (pA2 8.5), spiperone (pA2 7.3), indoramin (pA2 8.2) and BMY 7378 (pA2 6.6). These values correlated best with published pKi values for their displacement of [3H]-prazosin binding on membranes expressing cloned oczc-adrenoceptors and poorly with values from cloned lb- and cld-adrenoceptors.
    [Show full text]
  • Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No
    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
    [Show full text]
  • Adrenoceptors Regulating Cholinergic Activity in the Guinea-Pig Ileum 1978) G.M
    - + ! ,' Br. J. Pharmac. (1978), 64, 293-300. F'(O t.,," e reab- ,ellular PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC _-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM 1978) G.M. Departmentof Pharmacology,Allen and HzmburysResearchLimited, Ware, Hertfordshire,SG12 ODJ I The presynaptic ct-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to at-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ! ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch i response; the maximum inhibition obtained was 80 to 95_o of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 lag/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
    [Show full text]
  • 1. Generic Names Levosalbutamol 0.25G Ambroxol 7.5Mg
    1. Generic Names Levosalbutamol 0.25g Ambroxol 7.5mg Guaiphenesin 12.5 mg 2. Qualitative and Quantitative Composition Each ml contains Levosalbutamol 0.25g Ambroxol 7.5mg Guaiphenesin 12.5 mg 3. Dosage form and strength Oral drop solution containing Levosalbutamol 0.25g, Ambroxol 7.5mg, Guaiphenesin 12.5 mg. 4. Clinical particulars 4.1 Therapeutic indication Kofarest-PD drops is indicated for the treatment of productive cough associated with bronchospasm in conditions such as bronchitis and bronchial asthma as well as all conditions associated with tenacious mucus, wheezing and chest congestion. 4.2 Posology and method of administration The usual recommended dose of KOFAREST-PD Drops in children is: 1-2 years age: 0.8 ml thrice a day 2-3 years age: 1.2 ml thrice a day. 4.3 Contraindication Kofarest-PD drops are contraindicated in patients with hypersensitivity to any ingredient of the formulation. 4.4 Special warnings and precautions for use While treating cough as a symptom, it is important to make every effort to determine and treat appropriately the underlying cause, such as a specific infection. Caution should be observed while prescribing Kofarest-PD drops to children with hypertension, cardiovascular disease, uncontrolled juvenile diabetes mellitus, hyperthyroidism, and seizures or in patients who are unusually hypersensitive to sympathomimetic amines. 4.5 Drug interactions Hypokalaemia with high doses of ß2 -agonists may result in increased susceptibility to digitalis induced cardiac arrhythmias. Hypokalaemia may be enhanced by concomitant administration of aminophylline or other xanthine, corticosteroids or by diuretic therapy. Other sympathomimetic bronchodilators or epinephrine should not be used concomitantly with salbutamol, since their combined effect on the cardiovascular system may be deleterious to the patient.
    [Show full text]
  • Supplementary Materials 07/09/2017
    SMART Adolescent manuscript: Supplementary materials 07/09/2017 Supplementary materials Methods Definition and calculation of severe exacerbations The first three studies conducted 10-12, defined severe exacerbations as the need for oral corticosteroid (OCS) and/or hospitalisation/emergency room care due to asthma and/or a decrease in peak expiratory flow (PEF) of ≥30% on two consecutive days compared with the run-in period. In these studies, exacerbations were to be treated with a 10-day OCS course; an exacerbation lasting >10 days was considered a new exacerbation on the 11th day. Based on this experience, the later three studies 13-15 did not include falls in PEF in the exacerbation definition, nor this stipulated OCS treatment time, defining a severe exacerbation as the need for OCS for ≥3 days and/or hospitalisation/emergency room care due to asthma worsening. For the purpose of this analysis, we defined a severe exacerbation as the need for OCS (for ≥3 days 10-12) and/or hospitalisation/emergency room care due to asthma worsening; to align with this definition, data from 3 of the included studies 13-15 were reanalysed to exclude PEF fall from the exacerbation definition. 1 SMART Adolescent manuscript: Supplementary materials 07/09/2017 Literature review to identify any additional studies We conducted a review to identify any additional randomised controlled trials (RCTs) evaluating a combination of inhaled corticosteroids (ICS) and a rapid- acting bronchodilator in a single inhaler for both maintenance and as-needed relief of symptoms
    [Show full text]
  • Amcare Pharmaceuticals
    +91-8048558090 Amcare Pharmaceuticals https://www.indiamart.com/amcare-pharmaceuticals/ Founded in the year 2013, we “Amcare Pharmaceuticals” are a dependable and famous Manufacturer of a broad range of Pharmaceutical Tablets, Pharmaceutical Syrup, etc. About Us Founded in the year 2013, we “Amcare Pharmaceuticals” are a dependable and famous Manufacturer of a broad range of Pharmaceutical Tablets, Pharmaceutical Capsules, Pharmaceutical Syrup, etc. For more information, please visit https://www.indiamart.com/amcare-pharmaceuticals/profile.html PHARMACEUTICAL TABLETS O u r P r o d u c t R a n g e Anti Cold Tablets Telmisartan And Hydrochlorothiazide Tablets Ip, Minitel- H Paracetamol 60 Mg And Azithromycin 250MG Tablets, Caffeine 50 Mg Tablets IP 6 Tablets, Azimul-250 Tab Temperate-650 NF PHARMACEUTICAL SYRUP O u r P r o d u c t R a n g e Dextromethorphan Salbutamol, Ambroxol Phenylephrine Hydrochloride Hydrochloride, Guaiphenesin Chlorpheniramine Maleate Syrup Coffmul Sg Syrup Syrup, Coffmul- D 100 Ml Phenylephrine Hydrochloride Multivitamin & Multimineral And Chlorpheniramine With L- Lysine Health Maleate Syrup, Pedycold Supplement Syrup Syrup PHARMACEUTICAL CREAM O u r P r o d u c t R a n g e Itraconazole Ofloxacin Clotrimazole Cream IP Ornidazole And Clobetasol Propionate Cream Ketoconazole Cream Luliconazole Cream COUGH SYRUP O u r P r o d u c t R a n g e Dextromethorphan Dextromethorphan10 mg Hydrobromide Phenylephrine Phenylepherine5 mg Hydrochloride And Cpm Syrup Guaiphenasin100 mg Coffmul Dx Chlorpheniramine Maleate 4 mg Dextromethorphan
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Effects of Different Vasopressors on the Contraction of the Superior
    Wang et al. BMC Anesthesiology (2021) 21:185 https://doi.org/10.1186/s12871-021-01395-6 RESEARCH Open Access Effects of different vasopressors on the contraction of the superior mesenteric artery and uterine artery in rats during late pregnancy Tingting Wang1†, Limei Liao2†, Xiaohui Tang1, Bin Li1 and Shaoqiang Huang3* Abstract Background: Hypotension after neuraxial anaesthesia is one of the most common complications during caesarean section. Vasopressors are the most effective method to improve hypotension, but which of these drugs is best for caesarean section is not clear. We assessed the effects of vasopressors on the contractile response of uterine arteries and superior mesenteric arteries in pregnant rats to identify a drug that increases the blood pressure of the systemic circulation while minimally affecting the uterine and placental circulation. Methods: Isolated ring segments from the uterine and superior mesenteric arteries of pregnant rats were mounted in organ baths, and the contractile responses to several vasopressor agents were studied. Concentration-response curves for norepinephrine, phenylephrine, metaraminol and vasopressin were constructed. Results: The contractile response of the mesenteric artery to norepinephrine, as measured by the pEC50 of the drug, was stronger than the uterine artery (5.617 ± 0.11 vs. 4.493 ± 1.35, p = 0.009), and the contractile response of the uterine artery to metaraminol was stronger than the mesenteric artery (pEC50: 5.084 ± 0.17 vs. 4.92 ± 0.10, p = 0.007). There was no statistically significant difference in the pEC50 of phenylephrine or vasopressin between the two blood vessels. Conclusions: In vitro experiments showed that norepinephrine contracts peripheral blood vessels more strongly and had the least effect on uterine artery contraction.
    [Show full text]